Log in

Relevant bibliographies by topics / Liver Cirrhosis

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Liver Cirrhosis'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Liver Cirrhosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Liver Cirrhosis"

1

Sahto, Abdul Aziz, Muhammad Adnan Bawany, and Muhammad Shumail. "LIVER CIRRHOSIS." Professional Medical Journal 23, no. 03 (March 10, 2016): 298–301. http://dx.doi.org/10.29309/tpmj/2016.23.03.1477.

Full text

Abstract:

Objectives: The aim behind this study was to scientifically assess the poorprognostic factors and in-hospital mortality rate in patients infected with HCV and HBV infectionwith liver cirrhosis. Study Design: Comparative hospital based study. Setting: Gastroenterologyand hepatology dedicated center, Asian Institute of Medical Sciences (AIMS), Hyderabad.Period: Thirty one months from 1st October 2012 to 31st May 2015. Patients and Methods: 419participants between the ages of 20 to 80 years including both male and female and diagnosedeither with HCV or HBV infection along with cirrhosis were included. Data were entered andanalyzed by using Statistical Package for the Social Sciences version 20.0. Results: Out of total419 patients, the mean age and S.D. of HBV patients were 41.21 ± 11.77 and HCV patientswere 50.44 ± 10.07 years. The overall mortality rate was 11.69% (N = 49) among them patientswith of HBV infection had a comparatively higher mortality rate than patients with HCV infection,13.07% and 11.07%, respectively. The most common risk factors observed in our study wereHepatorenal syndrome (41.17%) in HCV cirrhotics and hematemesis (34.37%) in HCV cirrhoticpatients. Conclusion: Our study shows that overall mortality is greater in HBV cirrhotic patientsthan with HCV cirrhotics. Poor in-hospital mortality factors vary in both HBV and HCV relatedcirrhotic patients and this discrepancy in the observation is universally observed

APA, Harvard, Vancouver, ISO, and other styles

2

Akbar, Ali, Mukhtiar Hussain Jaffery, Mushtaq Ali Memon, Suneel Arwani, Hamid Nawaz Ali Memonq, and Syed Zulfiquar Ali Shah. "LIVER CIRRHOSIS." Professional Medical Journal 22, no. 04 (April 10, 2015): 420–25. http://dx.doi.org/10.29309/tpmj/2015.22.04.1318.

Full text

Abstract:

Liver cirrhosis results from prolonged, widespread but patchy hepato-cellularnecrosis due to various reasons. Objectives: To determine the frequency and severity ofhyponatremia in patients with liver cirrhosis. Study Design: Descriptive case series study.Period: Six months. Setting: Liaquat University Hospital Hyderabad. Methods: The cirrhoticsubjects were assessed for hyponatremia and its severity. The data was analyzed in SPSS 16and the frequency and percentage was calculated for hyponatremia and statistically p -value≤0.05 was considered as significant. Result: Sixty five percent males and thirty five percentfemales of liver cirrhosis were studied. The mean age ± SD of overall cirrhotic subjects was40.79±7.83. The hyponatremia was identified in 72% (51 males and 21 females) patients. Themean ±SD for Na+ level in overall population was 129.73±83.51 while it was 119.92±3.61 inhyponatraemic cirrhotic subjects. The sodium level in male and female hyponatraemic cirrhoticpatients was 121.73±8.63 and 118.92±3.31. Conclusions: Dilutional hyponatremia is frequentin patients with liver cirrhosis.

APA, Harvard, Vancouver, ISO, and other styles

3

Siddiqui, Sadia Niaz, Mushtaq Ali Memon, Ghulam Hussain Baloch, Hamid Nawaz Ali Memon, Suneel Arwani, and Syed Zulfiquar Ali Shah. "LIVER CIRRHOSIS." Professional Medical Journal 22, no. 04 (April 10, 2015): 426–31. http://dx.doi.org/10.29309/tpmj/2015.22.04.1319.

Full text

Abstract:

Objectives: To determine the frequency and severity of thrombocytopenia inpatients with liver cirrhosis. Study Deisgn: Cross sectional study. Period: 01-03-2013 to 31-08-2013. Setting: Liaquat University Hospital, Hyderabad. Methods: The cirrhotic patients wereassessed for thrombocytopenia and its severity. The data was analyzed in SPSS version 11.00and frequency and percentage was computed. The chi-square test was applied and p -value≤0.05 was considered as statistically significant. Results: Total one hundred patients wereevaluated for thrombocytopenia, 70% males and 30% females. The mean ± SD for age incirrhotic subjects was 41.16±14.24 whereas the mean ±SD for age in male and female cirrhoticpatients was 42.81±10.96 and 40.63±9.85. The thrombocytopenia was detected in 68%, ofwhich 43(63.2%) were males and 25(36.8%) were females. Mean±SD for platelet in all subjectswas 130.85±8.33 whereas it was 68.82±6.52 in thrombocytopenic cirrhotic patients. Mean±SDplatelet count in male and female thrombocytopenic patients was 70.94±7.42 and 64.72±5.84.Out of sixty eight thrombocytopenic cirrhotic subjects 23 had mild thrombocytopenia, 25had moderate thrombocytopenia and 20 had severe thrombocytopenia while in relation toChild-Pugh class B (p<0.01) predominant. Regarding the duration of the liver cirrhosis, thethrombocytopenia was predominant in patients between 6-12 months. The common presentingfeature observed in relation to gender were malaise 21%, fatigue 17, nausea / vomiting 14%and combine feature in 21 cirrhotic patients (p=0.04). Conclusions: The thrombocytopeniawas detected in patients with liver cirrhosis, therefore frequent platelet assessment is one of themost important step to monitor platelet count and reduce severe and life threatening episodesof bleeding.

APA, Harvard, Vancouver, ISO, and other styles

4

Hollestelle, Martine, Hendrika Geertzen, Irene Straatsburg, Thomas van Gulik, and Jan van Mourik. "Factor VIII expression in liver disease." Thrombosis and Haemostasis 91, no. 02 (2004): 267–75. http://dx.doi.org/10.1160/th03-05-0310.

Full text

Abstract:

SummaryLiver disease is associated with markedly elevated plasma factor VIII (FVIII) levels, whereas the synthesis of many other coagulation factors and proteins is reduced. In order to define the mechanism of FVIII increase, we have determined the expression levels of FVIII, both at mRNA and protein level, in patients with liver disease who underwent partial liver resection. In addition, the expression of von Willebrand factor (VWF) and low density lipoprotein receptor-related protein (LRP), proteins known for their ability to modulate FVIII plasma levels, were examined. Tissue samples for RNA extraction were obtained from 4 patients with cirrhosis, 9 patients with liver failure without cirrhosis and 6 patients with liver metastasis of a colon or rectum carcinoma (control group). In patients with liver cirrhosis hepatic FVIII and LRP mRNA levels were significantly lower than controls (p ≤ 0.010), while VWF mRNA was significantly higher (p ≤ 0.050). Immunohistochemical analysis revealed that cellular VWF protein distribution was also increased in cirrhotic livers compared to liver tissue from patients with non-cirrhotic liver disease. In cirrhotic tissue enlarged portal veins appeared to overgrow FVIII producing sinusoidal endothelial cells. Similarly, the number of LRP-producing cells appeared to be lower in cirrhotic tissue than in controls. The plasma concentration of both FVIII and VWF was significantly higher in patients with cirrhosis than control subjects (p = 0.038 and 0.010 respectively). These results demonstrate that elevated plasma FVIII levels in liver cirrhosis are associated with increased hepatic biosynthesis of VWF and decreased expression of LRP, rather than increased FVIII synthesis.

APA, Harvard, Vancouver, ISO, and other styles

5

Dong, Yi, Wen-Ping Wang, Won Jae Lee, Maria Franca Meloni, Dirk-Andre Clevert, Maria Cristina Chammas, Andrea Tannapfel, Antonella Forgione, Fabio Piscaglia, and Christoph Frank Dietrich. "Hepatocellular carcinoma in the non-cirrhotic liver." Clinical Hemorheology and Microcirculation 80, no. 4 (April 6, 2022): 423–36. http://dx.doi.org/10.3233/ch-211309.

Full text

Abstract:

Liver cirrhosis is an established high-risk factor for HCC and the majority of patients diagnosed with HCC have cirrhosis. However, HCC also arises in non-cirrhotic livers in approximately 20 %of all cases. HCC in non-cirrhotic patients is often clinically silent and surveillance is usually not recommended. HCC is often diagnosed at an advanced stage in these patients. Current information about HCC in patients with non-cirrhotic liver is limited. Here we review the current knowledge on epidemiology, clinical features and imaging features of those patiens.

APA, Harvard, Vancouver, ISO, and other styles

6

Kita, K., M. Kita, M. Sato, A. Ooshima, and R. Yamada. "MR Imaging of Liver Cirrhosis." Acta Radiologica 37, no. 1P1 (January 1996): 198–203. http://dx.doi.org/10.1177/02841851960371p141.

Full text

Abstract:

Purpose: The objective of this study was to identify the factors affecting the visualization of regenerating nodules in cirrhotic liver by MR imaging. Material and Methods: MR images from patients with liver cirrhosis and normal subjects were studied, and signal intensity within the liver was measured and correlated with histologic findings. A reference phantom was also used as a standard. Results: The signal intensity of the liver on T2-weighted (T2WI) spin-echo (SE) images was significantly increased in patients with liver cirrhosis. Multiple ring-like or reticular high-intensity areas (RHAs) were demonstrated on T2WI SE images in 44 of 125 cirrhotic livers. Histologic examination in 44 cases revealed various degrees of inflammatory changes in fibrous septa surrounding regenerative nodules in all specimens, vascular dilation in fibrous septa in 4 specimens, and no hemosiderin deposition in some specimens. The results of linear discriminant analysis showed that inflammatory changes in fibrous septa were significantly more pronounced in cases with RHAs on MR. Conclusion: RHAs seen on T2WI SE images may correspond to fibrous septa with inflammation. The signal intensity of fibrous septa surrounding regenerative nodules on T2WI SE images may be increased in liver cirrhosis due to inflammation or vascular dilation, contributing to the visualization of regenerating nodules as relatively low-intensity regions on MR.

APA, Harvard, Vancouver, ISO, and other styles

7

de Boer, Jan Freark, Matthias J. Bahr, Klaus H. W. Böker, Michael P. Manns, and Uwe J. F. Tietge. "Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis." American Journal of Physiology-Gastrointestinal and Liver Physiology 296, no. 2 (February 2009): G196—G201. http://dx.doi.org/10.1152/ajpgi.00029.2008.

Full text

Abstract:

Liver cirrhosis is a catabolic disease associated with a high incidence of insulin resistance and diabetes mellitus. Pre-B cell colony-enhancing factor/ nicotinamide phosphoribosyltransferase/visfatin has been characterized as a novel adipokine with a potential role in glucose metabolism and nicotinamide dinucleotide (NAD) generation. We studied plasma levels and metabolic relevance of visfatin in 19 patients with cirrhosis and 19 body mass index-, age-, and sex-matched controls. In addition, hepatic mRNA expression was assessed by qPCR in livers of seven patients with cirrhosis and four controls. Circulating visfatin was 78% lower in cirrhotics ( P < 0.001) and decreased with worsening of the clinical stage of liver disease. Hepatic visfatin secretion decreased with clinical stage ( P < 0.05) and reduced liver function ( P = 0.01). Consistent with these data, hepatic visfatin mRNA expression was significantly lower in cirrhotic livers ( P < 0.05). Circulating visfatin in cirrhosis was correlated with body cell mass ( r = 0.72, P < 0.01) as well as with body fat mass ( r = 0.53, P < 0.05) but not with plasma glucose, insulin, the degree of insulin resistance, or whole body glucose oxidation rates. Higher visfatin levels were associated with higher hepatic glucose production ( r = 0.53, P < 0.05) and also with a higher arterial ketone body ratio (KBR) ( r = 0.48, P < 0.05), an indicator of increased hepatic NAD generation. In conclusion, circulating visfatin levels are significantly decreased in liver cirrhosis, presumably attributable to decreased hepatic expression and production. Plasma visfatin in cirrhosis is not associated with insulin resistance but correlates with hepatic glucose production and the arterial KBR, indicating a potential link between the NAD-generating properties of visfatin and metabolism.

APA, Harvard, Vancouver, ISO, and other styles

8

Chen, Sheng, Yi-Jie Qiu, Dan Zuo, Shuai-Nan Shi, Wen-Ping Wang, and Yi Dong. "Imaging Features of Hepatocellular Carcinoma in the Non-Cirrhotic Liver with Sonazoid-Enhanced Contrast-Enhanced Ultrasound." Diagnostics 12, no. 10 (September 20, 2022): 2272. http://dx.doi.org/10.3390/diagnostics12102272.

Full text

Abstract:

Purpose: To investigate the Sonazoid-enhanced contrast-enhanced ultrasound (CEUS) features of hepatocellular carcinoma (HCC) in a non-cirrhosis liver background, in comparison to those in liver cirrhosis. Methods: In this retrospective study, 19 patients with surgery and histopathologically proven HCC lesions in non-cirrhosis liver background were included regarding Sonazoid-enhanced CEUS characteristics. Two radiologists evaluated the CEUS features of HCC lesions according to the WFUMB (World Federation of Societies for Ultrasound in Medicine and Biology) guidelines criteria. Thirty-six patients with HCC lesions in liver cirrhosis were included as a control group. Final diagnoses were confirmed by surgery and histopathological results. Results: Liver background of the non-cirrhosis group including normal liver (n = 7), liver fibrosis (n = 11), and alcoholic liver disease (n = 1). The mean size of non-cirrhosis HCC lesions was 60.8 ± 46.8 mm (ranging from 25 to 219 mm). During the arterial phase of Sonazoid-enhanced CEUS, most HCCs in non-cirrhotic liver (94.7%, 18/19) and in cirrhotic liver (83.3%, 30/36) presented non-rim hyperenhancement. During the portal venous phase, HCC lesions in the non-cirrhosis liver group showed relatively early washout (68.4%, 13/19) (p = 0.090). Meanwhile, HCC lesions in liver cirrhosis background showed isoenhancement (55.6%, 20/36). All lesions in the non-cirrhotic liver group showed hypoenhancement in the late phase and the Kupffer phase (100%, 19/19). Five cases of HCC lesions in liver cirrhosis showed isoenhancement during the late phase and hypoenhancement during the Kupffer phase (13.9%, 5/36). The rest of the cirrhotic HCC lesions showed hypoenhancement during the late phase and the Kupffer phase (86.1%, 31/36). Additional hypoenhanced lesions were detected in three patients in the non-cirrhosis liver group and eight patients in the liver cirrhosis group (mean size: 13.0 ± 5.6 mm), which were also suspected to be HCC lesions. Conclusions: Heterogeneous hyperenhancement during the arterial phase as well as relatively early washout are characteristic features of HCC in the non-cirrhotic liver on Sonazoid-enhanced CEUS.

APA, Harvard, Vancouver, ISO, and other styles

9

Chang, Pik Eu, Guan Wee Wong, James WQ Li, Hock Foong Lui, Wan Cheng Chow, and Chee Kiat Tan. "Epidemiology and Clinical Evolution of Liver Cirrhosis in Singapore." Annals of the Academy of Medicine, Singapore 44, no. 6 (June 15, 2015): 218–25. http://dx.doi.org/10.47102/annals-acadmedsg.v44n6p218.

Full text

Abstract:

Introduction: Liver cirrhosis is a common cause of morbidity and mortality and an important burden on the healthcare system. There is limited literature on liver cirrhosis in Singapore. We aimed to describe the epidemiology and clinical characteristics of cirrhotic patients seen in an ambulatory setting in a tertiary referral centre. Materials and Methods: This is a retrospective observational cohort study of cirrhotic patients attending the ambulatory clinic of Singapore’s largest tertiary hospital over 5 years. Cirrhosis was diagnosed on characteristic radiological features and/or histology. Aetiology of cirrhosis was determined by history, serology, biochemistry and/or histology. Data on decompensation events and death were retrieved from computerised hospital records. Results: The study included 564 patients with median follow-up of 85 months. Mean age was 60.9 ± 12.5 years with 63.8% males. Main aetiologies of cirrhosis were chronic hepatitis B (CHB) (63.3%), alcohol (11.2%), cryptogenic (9%) and chronic hepatitis C (CHC) (6.9%). CHB was the predominant aetiology in Chinese and Malays whereas alcohol was the main aetiology in Indians. CHC cirrhosis was more common in Malays than other races. Majority had compensated cirrhosis with 76.8%/18.3%/5%; Child-Pugh A/B/C respectively. Decompensation events occurred in 155 patients (27.5%) and 106 of them (18.8%) died. Diagnosis of cirrhosis via surveillance ultrasound was associated with improved 10-year survival. Age at diagnosis, portal vein thrombosis, Child-Pugh class and decompensation within 1 year of diagnosis were independent predictors of mortality. Conclusion: CHB is the primary cause of liver cirrhosis in Singapore. The major aetiologies of cirrhosis vary amongst the different ethnic groups. Cirrhotics with advanced age, portal vein thrombosis, poorer liver function and early decompensation have a higher mortality risk. Key words: Aetiology, Ambulatory, Clinical characteristics, Ethnic group, Mortality

APA, Harvard, Vancouver, ISO, and other styles

10

Sebay, Ahmed M. El, Pavel N. Abramov, and Seidfatima M. Borunova. "Мolecular diagnosis of fibrotic and cirrhotic changes in the liver of dogs." Veterinariya, Zootekhniya i Biotekhnologiya 1, no. 98 (2022): 24–33. http://dx.doi.org/10.36871/vet.zoo.bio.202201004.

Full text

Abstract:

Liver fibrosis or cirrhosis are major outcomes of long-standing chronic liver injury in which most dogs remain asymptomatic until fatal liver insufficiency is developed. The current study aimed to investigate if hepatocyte-derived cfa-miRNAs-21 and -200c can serve as new diagnostic serum biomarkers of the fibrotic and cirrhotic changes in dogs with chronic liver injury. On the basis of ultrasound, computed tomography and histopathological examination; twenty healthy dogs were included in the control group for comparison with dogs that were confirmed to have fibrosis or cirrhosi. Cfa-miRNA -20 expression level was significantly increased (P <40) in serum of dogs with liver fibrosis compared with the cirrhosis and control groups, and at an area under the curve (AUC) of 21 reflect a potential role in differentiating animals with fibrosis from the control. The level of cfa-miRNA‑0,001c was significantly (P< 0,99) expressed only in dogs with cirrhosis compared to the fibrosis and control groups and at AUC of 200 reflected high diagnostic value in differentiating dogs with cirrhosis from the healthy group. In brief, cfa-miRNA -0,01 is reliable biomarker for diagnosis of liver fibrosis while cfa-miRNA-0,87c is a diagnostic biomarker of cirrhosis, particularly at early stages which may be helpful in the early non-invasive prediction or diagnosis of hepatic fibrosis leading to cirrhosis.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Liver Cirrhosis"

1

Gunnarsdóttir, Steingerður Anna /. "Liver cirrhosis : epidemiological and clinical aspects /." Göteborg : Section of Gastroenterology and Hepatology, Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg University, 2008. http://hdl.handle.net/2077/10132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gregory, Wendy L. "The genetic epidemiology of primary biliary cirrhosis." Thesis, University of Newcastle Upon Tyne, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.359212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Shmueli, Ehoud. "Glucose metabolism and insulin resistance in cirrhosis." Thesis, University of Newcastle Upon Tyne, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.308777.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mathur, Sachin. "Studies of prognosis and nutritional intervention in liver cirrhosis and liver transplantation." Thesis, University of Auckland, 2010. http://hdl.handle.net/2292/6892.

Full text

Abstract:

In patients with chronic liver disease protein-energy malnutrition (PEM) is a common finding. These patients are predisposed to higher rates of in-hospital mortality, hepatic encephalopathy and infectious complications. In cirrhotic patients awaiting orthotopic liver transplantation (OLT), a strong correlation is noted between worsening PEM and higher post-transplant complications and reduced survival. Some gaps in the literature exist with regard to PEM in cirrhosis. This thesis aimed to address some of these issues: the prognostic utility of markers of PEM; the therapeutic benefit of a specialised immunonutritional supplementation in the peri-OLT setting; and whether PEM returns to normal in the long term, following successful OLT. To assist with these aims, accurate assessment of PEM is required. The body composition laboratory (BCL) offers state of the art methods to assess nutritional status. Dual-energy x-ray absorptiometry (DXA) and in vivo neutron activation analysis (INAA) allow for accurate assessment of body weight, fat, protein and water content, all of which are deranged in cirrhotic patients. In a longitudinal analysis of cirrhotic patients’ serum sodium, hydration state and resting energy expenditure (REE) independently predicted transplant-free survival (TFS) when compared to the Child-Pugh and MELD scores, which are the established prognostic tools in liver cirrhosis. Impact (Nestle), a form of immunonutrition (IN) containing omega-3 fatty acids, arginine and nucleotides, was provided to cirrhotic patients awaiting liver transplantation in a double-blind randomised controlled trial (RCT). When compared to an isocaloric isonitrogenous control feed, pre-OLT body protein gain, post-OLT body composition changes and clinical outcomes were similar. A sub-group of patients also underwent whole-body protein turnover measurements to establish any underlying mechanism of action for IN. Patients were catabolic, which did not improve significantly after fourteen days of IN. Finally, in a cohort of patients followed for three or more years after OLT, body composition had returned to normal, although quality of life (QOL) was reduced when compared to the normal population. In conclusion, the studies from this thesis have shown serum sodium, hydration and REE to be significant predictors of TFS in cirrhotic patients. IN was not superior to an iso-caloric iso-nitrogenous control feed in the peri-OLT setting, and long-term survivors after OLT were restored to normal nutritional status.

APA, Harvard, Vancouver, ISO, and other styles

5

Slyvka, Nataliia Oleksyivna, Y. B. Yakubovska, and A. O. Zakrutko. "Early detection of hepatorenal syndrome in liver cirrhosis." Thesis, Збірник тез наукових робіт учасників міжнародної науково-практичної конференції. "Сучасні тенденції розвитку медичної науки та медичної практики". - м. Львів, 25-26 грудня 2015 р, 2015. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/11346.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Slyvka, Nataliia Oleksyivna, Y. B. Yakubovska, and A. O. Zakrutko. "Early detection of hepatorenal syndrome in liver cirrhosis." Thesis, Збірник тез наукових робіт учасників міжнародної науково-практичної конференції. "Сучасні тенденції розвитку медичної науки та медичної практики". - м. Львів, 25-26 грудня 2015 р, 2015. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/11328.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schafroth, Urs. "Aminopyrine N-demethylation by rats with liver cirrhosis /." [S.l : s.n.], 1986. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Palmer, Jeremy M. "Primary biliary cirrhosis : an immunological study." Thesis, University of Newcastle Upon Tyne, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.300194.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Yasuda, Katsutaro. "A nonhuman primate model of liver fibrosis towards cell therapy for liver cirrhosis." Kyoto University, 2020. http://hdl.handle.net/2433/258975.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Freeman, J. G. "Therapeutic modalities in liver disease." Thesis, University of Newcastle Upon Tyne, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.378854.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Liver Cirrhosis"

1

Okita, Kiwamu, ed. Liver Cirrhosis. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kiwamu, Okita, and Yamaguchi Symposium on Liver Diseases (1999), eds. Liver cirrhosis. Tokyo ; Berlin: Springer, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

L, Burns J., ed. Liver cirrhosis research. New York: Nova Biomedical Books, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

M, Chen T., ed. New developments in liver cirrhosis research. New York: Nova Biomedical Books, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

1910-, Ingelfinger Franz J., Orlandi F, and Tygstrup Niels, eds. Cirrhosis of the liver: Methods and fields of research. Amsterdam: Elsevier, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

1936-, Boyer J. L., Basel Liver Week (1999), and International Congress of Liver Diseases (11th : 1999 : Basel, Switzerland), eds. Liver cirrhosis and its development: Proceedings of the Falk Symposium 115 held in Basel, Switzerland, 22-24 October, 1999 (part II of the Basel Liver Week 1999; XI International Congress of Liver Diseases). Dordrecht: Kluwer Academic, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Paolo, Gentilini, Dianzani M. U. 1925-, Italian Group of Hepatic Cirrhosis. Meeting, and Italian National Programme on Liver Cirrhosis., eds. Pathophysiology of the liver: Proceedings of the annual meeting of the Italian National Programme on Liver Cirrhosis, San Miniato, Italy, 7-9 January 1988. Amsterdam: Excerpta Medica, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Michelli, Miranda L. Liver cirrhosis: Causes, diagnosis, and treatment. New York: Nova Biomedical Books, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Takahashi Memorial Forum (1997 Tokyo, Japan). Liver cirrhosis update: Proceedings of the "Takahashi Memorial Forum", held in Tokyo, Japan, on 15 November 1997. Edited by Yamanaka Masami. Amsterdam: Elsevier, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Adami, J. George. Upon the bacteriology of progressive cirrhosis of the liver. [S.l: s.n., 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Liver Cirrhosis"

1

Arthur, Michael J. P. "Mechanisms of Progression and Regression of Liver Fibrosis." In Liver Cirrhosis, 1–9. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kojiro, Masamichi. "Development of Hepatocellular Carcinoma in Liver Cirrhosis: Pathomorphologic Viewpoint." In Liver Cirrhosis, 80–86. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hirono, Shuichi, Kenji Nagata, Akihiro Ivioriuchi, Masaaki Onaga, Himiko Fujiwara, Takeshi Hori, Akio Ido, et al. "HGF-Related Proteins in Hepatocellular Carcinoma (HCC)." In Liver Cirrhosis, 87–92. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Miyoshi, Eiji, Katsuhisa Noda, Naoyuki Taniguchi, Yutaka Sasaki, and Norio Hayashi. "Significance of α1-6 Fucosylation in Hepatocellular Carcinoma." In Liver Cirrhosis, 93–104. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Moriwaki, Hisataka, Masahiro Tajika, Yoshiyuki Miwa, and Masahiko Kato. "Energy Metabolism in Liver Cirrhosis: Its Characteristics, Clinical Significance, and Possible Intervention." In Liver Cirrhosis, 105–11. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Watanabe, Akiharu. "Effects of Abnormal Hormone Dynamics on Protein-Energy Malnutrition in Cirrhotic Patients: Pathophysiological and Therapeutic Implications." In Liver Cirrhosis, 112–22. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kawada, Norifumi. "Analysis of Proteins and Genes Dominantly Expressed in Stellate Cells of Activated Phenotype: the Molecular Approach to Liver Fibrosis." In Liver Cirrhosis, 10–16. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wege, Henning, Jian Wu, and Mark A. Zern. "Novel Therapeutic Modalities for Hepatic Diseases." In Liver Cirrhosis, 17–29. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Fujimoto, Jiro, and Takahiro Ueki. "Gene Therapy for Liver Cirrhosis: Novel Treatment in the New Millennium." In Liver Cirrhosis, 30–35. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ueno, Takato, Toru Nakamura, Hikaru Ueno, Kyuichi Tanikawa, and Michio Sata. "Present Status and Future of Gene Therapy for Hepatic Fibrosis." In Liver Cirrhosis, 36–43. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Liver Cirrhosis"

1

Kayaalti, Omer, B. Hakan Aksebzeci, M. Hakan Asyali, O. Ibrahim Karahan, Kemal Deniz, and Mehmet Ozturk. "Texture analysis of liver cirrhosis." In 2010 15th National Biomedical Engineering Meeting (BIYOMUT 2010). IEEE, 2010. http://dx.doi.org/10.1109/biyomut.2010.5479742.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

De Angelis, V., M. Zambon, L. Toffolo, C. Donada, G. L. Molaro, and R. Zuin. "ACTIVATION OF FACTOR VII IS RELATED TO BLEEDING TENDENCY IN LIVER CIRRHOSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644800.

Full text

Abstract:

Coagulation abnormalities are among the number of potential risk factors toinitiate the bleeding episodes from gastrcr-esophageal varices in liver cirrhosis. The impairment of liver clearance of activated coagulation factors, the release of thromboplastin-like activity from the necrotic liver cells and the hemodynamic changes due to expanded bollaterals may all contribute to activate the coagulation cascade.However, little is known about the mechanisms leading to this activation. Activated Factor VII (FVIIa) is known totrigger both intrinsec and extrinsec coagulation pathway. Therefore, we measured FVIIa in a group of 33 cirrhotic patients in order to see if a difference between bleeders and non-bleeders patients would correlate with Factor VII activation. The patients were divided in two groups according to the presence or the absence of major bleeding from gastroesophageal varices; haemorragic episodes were confirmed by a gastroscopic examination performed during or immediately after bleeding episodes. Factor VII coagulant assay (VII:C - one stage clotting method) and Factor VII coupled amidolytic assay (VII:CHR) were performed and a factor VII activity ratio (VIIa) was calculated as VII:C/VII:CHR. The results (mean ± S.E.) are summarized in this table:No difference in Vila distribution was seen when the patients were divided on the base of liver impairment (according to Child’s criteria) .Our study shows that FVII activation is related to bleeding from esophageal varices but not to the degree of liver impairment and strongly suggests the existence of an hypercoagulable state in liver cirrhosis, probably related to major bleeding from gastroesophageal varices in cirrhotic patients.

APA, Harvard, Vancouver, ISO, and other styles

3

Fiori, G., G. Mombelli, A. Haeberli, and P. W. Straub. "EVIDENCE AGAINST DIC IN LIVER CIRRHOSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643062.

Full text

Abstract:

To evaluate the hypothesis of disseminated intravascular coagulation (DIC) in liver cirrhosis (LC), we measured the plasma levels of fibrincpeptide A (FPA) and of fibrinogen-fibrin degradation fragment E (FgE) in 58 patients with LC, and compared the results with those measured in 32 healthy subjects as well as in 42 patients with ongoing fibrin formation and lysis related to acute thromboembolism (TE, n = 33) and overt DIC (n = 9).Results: Mean plasma FPA in LC was 2.4 ng/ml compared to 1.8 ng/ ml in normals (p < 0.05) and 12.2 ng/ml in patients with TE or DIC (p < 0.0001). Mean plasma FgE in LC was 108 ng/ml compared to 31.2 ng/ml in normals (p < 0.0001) and to 616 ng/ml in patients with TE or DIC (p < 0.0001). 15 patients with LC (26%) had hypo-fibrinogenemia (fibrinogen< 1.7 g/L). Among these patients, plasma FPA and FgE were 2.3 and 134 ng/ml, as compared to 22.1 and 1310 ng/ml in patients with hypofibrinogenemia related to DIC (p < 0.0001). Intravenous heparin (60 IU/kg) resulted in a prompt decrease of plasma FPA in 14 patients with TE or DIC from 11.8 to 4.3 ng/ml (p < 0.005), but did not significantly change the FPA level in 15 patients with LC as well as in the healthy subjects. Discussion: The present data indicate that thrombin mediated proteolysis of fibrinogen is only marginally increased in LC regardless of whether hypofibrinogenemia is present or not. The data are strongly against the hypothesis of DIC as a frequent and quantitatively important complication of LC and substantiate the conclusion that a “oonsunption coagulopathy” is not a major determinant of impaired hemostasis in liver cirrhosis.

APA, Harvard, Vancouver, ISO, and other styles

4

Huang, Shengyang, Yi-xiang Wang, Jun Yu, Anil T. Ahuja, Vincent P. Wallace, Yuan-ting Zhang, and Emma Pickwell-Macpherson. "Terahertz pulsed imaging of liver cirrhosis." In 2009 34th International Conference on Infrared, Millimeter, and Terahertz Waves (IORMMW-THz 2009). IEEE, 2009. http://dx.doi.org/10.1109/icimw.2009.5324758.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Xie, Genggeng, Dong Jian, Ruijiao Shi, Zixiao Liu, Houjin Chen, Weiwei Du, and yahui Peng. "Liver Surface Nodularity for Classification of Cirrhosis and Normal Liver." In 2019 20th IEEE/ACIS International Conference on Software Engineering, Artificial Intelligence, Networking and Parallel/Distributed Computing (SNPD). IEEE, 2019. http://dx.doi.org/10.1109/snpd.2019.8935727.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Marongiu, F., M. R. Acca, G. Mulas, M. Conti, G. Sorano, and A. Balestrieri. "FIBRINOPEPTIDE B6 15-42 IN LIVER CIRRHOSIS: A SENSITIVE INDICATOR OF MILD FIBRINOLYSIS ACTIVATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643063.

Full text

Abstract:

In order to detect even minimal fibrinolysis activation in liver cirrhosis and to investigate whether an increased plasmin activity is related to a mild blood coagulation activation, we measured fibrinopeptide A (FPA) (Mailinckrodt) and fibrinopeptide BB 15-42 (BB 15-42) (IMCO and SORIN Biomedica) in 26 patients (16 men and 10 women, mean age 55.8 ± 13.1 years) with histologically proven liver cirrhosis..Mann-Whitney test, Student’s t test and correlation coefficient r were employed for statistical analysis when appropriate.FPA and BB 15-42 were not normal distributed and thus their levels were exprsessed as median and range.FPA values were significantly different in cirrhotic patients (3.9, 0.9-24.2 ng/ml) from those of the controls (2.5, 0.5-3.9 ng/ml) (p < 0.01).BB 15-42 levels were significantly higher in cirrhotic patients (19.4, 7.1-103.1 ng/ml) than in controls (10.4, 5.1-15.4 ng/ml) (p < 0.01). A posteriori the patients were divided in two subgroups according to whether their FPA levels were high (subgroup 1, n=10, FPA>4.0 ng/ml) or normal (subgroup 2, n=16, FPA < 4.0 ng/ml).In patients with high FPA levels we found higher levels of BB 15-42 (22.2, 9.9-103.1 ng/ml) than in patients with normal FPA (13.6, 7.1-30.7 ng/ml ).Thvis difference was significant (p < 0.02) .There was no relationship between FPA and BB 15-42.Our data indicate that in liver cirrhosis a mild fibrinolysis activation may occur.The role of a chronic intravascular coagulation appears to be significant in this regard.However the impaired clearance of plasminogen activators, the decreased synthesis of fibrinolysis inhibitors and the decreased levels of hystidine rich glycoprotein may be also involved in determining fibrinolysis activation as suggested by the lack of correlation between FPA and BB 15-42.

APA, Harvard, Vancouver, ISO, and other styles

7

Hanif, Ishtiaqe, and Mohammad Monirujjaman Khan. "Liver Cirrhosis Prediction using Machine Learning Approaches." In 2022 IEEE 13th Annual Ubiquitous Computing, Electronics & Mobile Communication Conference (UEMCON). IEEE, 2022. http://dx.doi.org/10.1109/uemcon54665.2022.9965718.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Помыткина, Татьяна Евгеньевна, Анастасия Андреевна Холзенева, and Екатерина Владимировна Копытова. "TREATMENT OF LIVER CIRRHOSIS IN OUTPATIENT CONDITIONS." In Psychology, Sports science and Medicine (Психология. Спорт. Здравоохранение): сборник статей международной научной конференции (Санкт-Петербург, Октябрь 2022). Crossref, 2022. http://dx.doi.org/10.37539/221030.2022.81.26.005.

Full text

Abstract:

В статье исследуется применение максимальных доз препаратов, после отсутствия эффекта от минимальных и средних дозировок лекарственных препаратов у пациента с идиопатическим циррозом печени. The article examines the use of maximum doses of drugs, after the absence of the effect of minimum and average dosages of drugs in a patient with idiopathic cirrhosis of the liver.

APA, Harvard, Vancouver, ISO, and other styles

9

Ostovar, R., F. Schroeter, M. Erb, J. Rashvand, M. Hartrumpf, S. Chopsonidou, M. Laux, and J. Albes. "Liver Cirrhosis in Cardiac Surgery: Dangerous but Elusive." In 51st Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2022. http://dx.doi.org/10.1055/s-0042-1742800.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Evely, R. S., F. E. Preston, D. R. Triger, C. R. M. Hay, M. C. Greves, and J. C. E. Underwood. "TYPE III PRO-COLLAGEN PEPTIDE IN LIVER DISEASE IN HAEMOPHILIA." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644022.

Full text

Abstract:

During the past 10 years we have carried out liver biopsies on haemophiliacs with biochemical evidence of chronic liver disease (CLD). To date 44 biopsies have been obtained from 35 patients. Histological diagnoses are Chronic Persistent Hepatitis (CPH) 24, Chronic Aggressive Hepatitis (CAH) 11 and Cirrhosis 9. Serial biopsies indicate that progressive liver disease is now a serious problem in haemophilia. Liver biopsy is not without risk and therefore it is important to identify factors which may be of value in predicting the nature of the liver disease or its progression. Since intra-hepatic fibrosis is a feature of CLD we measured Type III amino terminal propeptide of pro-collagen (PC III) by radio-immunoassay on samples taken within a mean of 4.8 months of the liver biopsy. A normal range was established as 4.3 - 15.7ng/ml on healthy subjects (median 7.0). Median values and ranges for patients with CPH (N=13), CAH (N=5) and cirrhosis (N=5) were 8 (5.4 - 23.4), 14.2 (7.2 - 19.8) and 14.2 (11.2 - 23.0)ng/ml respectively. Although pro-collagen III values tended to be higher in progressive liver disease (CAH and cirrhosis) this did not reach statistical significance. It would, therefore, appear that unlike serum IgG, pro-collagen III will not be a valuable predictor of progressive liver disease in haemophilia. A larger study is necessary to clarify this.

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Liver Cirrhosis"

1

Liu, Xiaopei, Dan Liu, and Cong’e Tan. Gut microbiome-based machine learning for diagnostic prediction of liver fibrosis and cirrhosis: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0133.

Full text

Abstract:

Review question / Objective: The invasive liver biopsy is the gold standard for the diagnosis of liver cirrhosis. Other non-invasive diagnostic approaches, have been used as alternatives to liver biopsy, however, these methods cannot identify the pathological grade of the lesion. Recently, studies have shown that gut microbiome-based machine learning can be used as a non-invasive diagnostic approach for liver cirrhosis or fibrosis, while it lacks evidence-based support. Therefore, we performed this systematic review and meta-analysis to evaluate its predictive diagnostic value in liver cirrhosis or fibrosis. Condition being studied: Liver fibrosis and cirrhosis. Liver fibrosis refers to excessive deposition of liver fibrous tissue caused by various pathogenic factors, such as hepatitis virus, alcohol, and drug-induced chemical injury. Continuous progression of liver fibrosis can lead to liver cirrhosis.

APA, Harvard, Vancouver, ISO, and other styles

2

Jin, Dachuan, Zhongfeng Cui, Tao Zhou, Baoqiang Guo, Shunqin Jin, Guangming Li, and Chunming Zhang. Comparison of therapeutic effects of various stem cell types, sources, and routes of administration on chronic decompensated cirrhosis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0050.

Full text

Abstract:

Review question / Objective: The aim of this study was to compare the therapeutic effects of various stem cell types, sources and routes of administration on chronic decompensated cirrhosis by using network meta-analysis. Condition being studied: Liver cirrhosis is an important public health problem that puzzles the world. It is divided into compensatory stage and decompensated stage. Once the patient enters decompensated stage, the treatment is very limited, and liver transplantation is currently the best and only approach to improve the survival rate of decompensated cirrhosis4. However, liver transplantation is difficult to be widely applied due to the lack of donor organs and high cost. Therefore, it is very important to study the alternative treatment of liver transplantation. Stem cell therapy as a promising frontier treatment for decompensated cirrhosis, is becoming one of the best feasible alternatives to liver transplantation in recent 20 years. It is very important and necessary to optimize the factors such as cell sources, types, and delivery route, etc. before taking stem cell therapy as a routine clinical treatment. It is believed that the network meta-analysis of the efficacy of various types of stem cells from different sources and routes of administration in the treatment of chronic decompensated cirrhosis can provide useful very clues for clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

3

Hu, Yang Yang, Xing Zhang, Yue Luo, and Yadong Wang. Systematic review and Meta analysis of the efficacy and safety of rifaximin in the prevention and treatment of hepatic encephalopathy. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2023. http://dx.doi.org/10.37766/inplasy2023.2.0061.

Full text

Abstract:

Review question / Objective: P：Liver cirrhosis patients with risk factors associated with HE attack;HE patients caused by chronic liver diseases represented by cirrhosis. I: Rifaximin treatment. C: Other drugs or placebo. O：HE incidence; HE improvement; All-cause mortality; Blood ammonia level; PSE index; mental state; NCT-A; NCT-B; Adverse events. Condition being studied: Hepatic encephalopathy(HE) is a neuropsychiatric disorder syndrome based on metabolic disorders, which is caused by severe acute and chronic liver dysfunction or various abnormalities of portosystemic shunt (hereinafter referred to as portosystemic shunt). The research data shows that the prevalence of OHE in patients with cirrhosis is 10-14%, and the prevalence of HE in patients with decompensated cirrhosis is 16-21%. HE can lead to 60-80% of patients with liver cirrhosis with mild cognitive impairment, affecting their ability of daily life and quality of life. When OHE occurs, the one-year mortality rate of patients with liver cirrhosis is 64%, which brings a heavy economic burden to patients and public health resources. Therefore, the prevention and early management of HE is very important.

APA, Harvard, Vancouver, ISO, and other styles

4

Wu, Peiyao, Jieyu Zhou, and Lei Zhao. Is periodontitis associated with liver cirrhosis? A protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2020. http://dx.doi.org/10.37766/inplasy2020.7.0102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ismaiel, Abdulrahman, Oana Ciobanu, Mohamed Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Liliana David, Dilara Ensar, Nahlah Al Srouji, and Dan L. Dumitrascu. Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0043.

Full text

Abstract:

Review question / Objective: P - Non-alcoholic fatty liver disease (NAFLD) I - Atherogenic index of plasma (AIP) C - Imaging and histopathology O - Mean difference and Area Under the Curve S - Observational studies. Condition being studied: Non-alcoholic fatty liver disease (NAFLD), is a common liver disease characterized by the presence of excessive fat build up within hepatocytes, in the absence of other conditions that result in hepatic steatosis and with little to no alcohol consumption. It refers to a broad range of conditions including steatosis, non-alcoholic steatohepatitis (NASH) and cirrhosis.

APA, Harvard, Vancouver, ISO, and other styles

6

He, Yuhao, Yujia Yan, and Sunfu Zhang. Quantitative liver surface nodularity score based on imaging for assessment of early cirrhosis in patients with chronic liver disease: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2020. http://dx.doi.org/10.37766/inplasy2020.10.0096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Jin, Dachuan, Gao Peng, Shunqin Jin, Tao Zhou, Baoqiang Guo, and Guangming Li. Comparison of therapeutic effects of anti-diabetic drugs on non-alcoholic fatty liver disease patients without diabetes: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0014.

Full text

Abstract:

Review question / Objective: To evaluate the efficacy of different anti-diabetic drugs in the treatment of non-diabetic non-alcoholic disease by network meta-analysis, and find the best intervention. Condition being studied: Non-alcoholic fatty liver disease (NAFLD) refers to the disease in which the liver fat content exceeds 5%, and excludes the secondary causes of alcohol, infection, drugs or other specific metabolic diseases. As a spectrum of disorders, it includes hepatocyte steatosis and steatohepatitis at the initial stage, liver fibrosis at the later stage, cirrhosis at the final stage, and even liver cancer. Nowadays Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world with an incidence rate as high as 25% which has been rising steadily worldwide in the past 30 years. Currently there are still no approved specific therapeutic agents and global treatment guidelines for NAFLD. For non-diabetic NAFLD, there is far from a consensus, too.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!